By increasing GLP-1 production or stimulating its release, this approach can complement existing therapies, such as GLP-1RAs and DPP-4 inhibitors, offering additional benefits while potentially reducing side effects
Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects
10.3389/fnmol.2023.1163981 147 YangS.ThackrayA
We now have a viable treatment option for children who have obesity, for whom lifestyle therapy is simply insufficient, said lead author Claudia Fox, co-director of the Center for Pediatric Obesity Medicine at University of Minnesota Medical School
[21] Niacin, especially in high doses, can cause hyperuricemia
Theres also another form of semaglutide that is FDA-approved for weight management, called Wegovy, which is given as a weekly injection